Picomole Receives Canadian Patent Notice of Allowance for its Breath Analysis Technology
MONCTON, NEW BRUNSWICK--(Marketwire - Sep 19, 2012) - Picomole Instruments Inc., the world leader in infrared technologies for breath analysis, announced today that it has received a Patent Notice of Allowance from the Canadian Intellectual Property Office for its innovative technology to rapidly analyze complex gas mixtures like exhaled breath.
Picomole''s technology represents a major advance in the field of breath analysis. It permits easy sample analysis of hundreds of volatile compounds found in breath at parts-per-billion levels and below within minutes. This allows laboratory-quality analyses to be performed by clinicians in point-of-care settings using an easy-to-use, portable device.
Exhaled breath contains trace compounds linked to breast cancer, lung cancer, kidney disease and many other life-threatening medical conditions. Breath tests for such diseases would be fast, painless, non-invasive, and cost effective.
"Notification that the patent will be issued in Canada validates seven years of research and development by our dedicated team of scientists and engineers. Our infrared laser-based technology is unique and clearly differentiated from other gas analysis technologies" said Dr. John Cormier, Founder and CEO of Picomole Instruments Inc. "Today''s press release builds on the U.S. Patent Notice of Allowance we recently announced, and further strengthens our ability to broadly protect our proprietary technology as we develop clinical applications."
Picomole is currently forging collaborations with leading clinical research groups in Canada and around the world, and expects to make additional announcements in the months ahead.
Picomole would like to acknowledge the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for its longstanding support and technical advice.
